Adult T-cell leukemia future or investigational therapies: Difference between revisions
(Category) |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Adult T-cell leukemia}} | {{Adult T-cell leukemia}} | ||
Molecular targeting therapy like targeting therapy against ''NOTCH1''/''FBXW7'' mutations, JAK-STAT signaling pathway and inhibition of the PI3K-signaling pathway are the future investigation therapy for adult t-cell leukemia. | |||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 18:38, 25 November 2018
|
Adult T-cell leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Adult T-cell leukemia future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Adult T-cell leukemia future or investigational therapies |
|
FDA on Adult T-cell leukemia future or investigational therapies |
|
CDC on Adult T-cell leukemia future or investigational therapies |
|
Adult T-cell leukemia future or investigational therapies in the news |
|
Blogs on Adult T-cell leukemia future or investigational therapies |
|
Risk calculators and risk factors for Adult T-cell leukemia future or investigational therapies |
Molecular targeting therapy like targeting therapy against NOTCH1/FBXW7 mutations, JAK-STAT signaling pathway and inhibition of the PI3K-signaling pathway are the future investigation therapy for adult t-cell leukemia.